CA
IONS icon

Centerpoint Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Centerpoint Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-68
Closed -$3K – 508
2023
Q3 		$3K Hold
68
– – ﹤0.01% 420
2023
Q2 		$3K Hold
68
– – ﹤0.01% 424
2023
Q1 		$2K Hold
68
– – ﹤0.01% 439
2022
Q4 		$3K Hold
68
– – ﹤0.01% 377
2022
Q3 		$3K Hold
68
– – ﹤0.01% 293
2022
Q2 		$3K Hold
68
– – ﹤0.01% 301
2022
Q1 		$3K Hold
68
– – ﹤0.01% 306
2021
Q4 		$2K Buy
+68
New +$2.14K ﹤0.01% 335

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Centerpoint Advisors's IONS Position: Q4 2023 in Review

Centerpoint Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2023, closing a stake of 68 shares — an estimated $3K sold.

Centerpoint Advisors first reported a position in IONS in Q4 2021 and held it in 8 quarters. The position peaked at $3K in Q3 2023. 363 funds tracked by Wall St. Rank hold IONS as of Q4 2023.

  • Centerpoint Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centerpoint Advisors sold 68 Ionis Pharmaceuticals shares in Q4 2023, an estimated $3K.
  • Centerpoint Advisors first reported a position in Ionis Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Centerpoint Advisors's Ionis Pharmaceuticals position peaked at $3K in Q3 2023.
  • 363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2023.

Based on Centerpoint Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.